Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The importance of patient-reported outcomes in clinical trials & clinical practice

Anna Sureda • 12 Jun 2022
EHA 2022
General

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the importance of including patient-reported outcomes in prospective clinical trials and in clinical practice. Dr Sureda explains that in clinical practice, a treatment that is better tolerated and has a lesser impact on the patient’s quality of life (QoL) is usually favored. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Honoraria: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, Alexion
Consultancy: Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi
Speaker’s Bureau: Takeda
Research support: Takeda, BMS/Celgene

More from Anna Sureda

Overcoming common misconceptions about CAR-T in DLBCL
3:43
Overcoming common misconceptions about CAR-T in DLBCL
Anna Sureda • 18 Mar 2026
Integrating bispecific antibodies into the transplant strategy for B-cell non-Hodgkin lymphomas
2:56
Integrating bispecific antibodies into the transplant strategy for B-cell non-Hodgkin lymphomas
Anna Sureda • 18 Mar 2026
Insights into the EBMT Consensus on transplantation in Hodgkin lymphoma
4:20
Insights into the EBMT Consensus on transplantation in Hodgkin lymphoma
Anna Sureda • 18 Mar 2026
Register for the fast-approaching 52nd Annual Meeting of the EBMT
1:21
Register for the fast-approaching 52nd Annual Meeting of the EBMT
Anna Sureda • 18 Mar 2026

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals